Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life

Donald D. Chang, Harris A. Eyreeuro, Ryan Abbott, Michael Coudreaut, Bernhard T. Baune, Jeffrey A. Shaman, Helen Lavretsky, Eric J. Lenze, David A. Merrill, Ajeet B. Singh, Benoit H. Mulsant, Charles F. Reynolds, Daniel J. Müller, Chad Bousman

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.

Original languageEnglish
Pages (from-to)1269-1284
Number of pages16
JournalPharmacogenomics
Volume19
Issue number16
DOIs
StatePublished - Nov 2018

Keywords

  • decision support tools
  • late-life depression
  • major depression
  • pharmacogenomics
  • precision medicine

Fingerprint Dive into the research topics of 'Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life'. Together they form a unique fingerprint.

Cite this